Stock Updates

A look at a High Market Cap Stock: GlaxoSmithKline plc, GSK

GlaxoSmithKline plc, GSK is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in United Kingdom, GlaxoSmithKline plc, GSKĀ  has a market cap of 109372.01. Since its IPO date on the 7/9/1986, GlaxoSmithKline plc, GSK performance year to date is 16.66%. Today GlaxoSmithKline plc, GSK has gained 0.30%, with a current price of 45.17.

Ownership of the company is 0.20% for insider ownership while institutional ownership is 8.80%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at 0.10%, with return on investment at 41.40%.

In terms of debt levels and profit levels, GlaxoSmithKline plc, GSK is seeing a long-term debt/equity of 26.3. While Total debt/equity is 34.11. With a profit margin of 0.10%, this is combined with a gross margin of 66.60%, and operating margin of 5.30%. GlaxoSmithKline plc ability to meet debt levels, with a current ratio of 0.9, while the quick ratio is 0.6.

For the last year GlaxoSmithKline plc, GSK has seen a EPS growth of 204.10%. A performance for the year of 11.36%. The 52-week high is -0.91%, and the 52-week low is 28.59%. The average volume for GlaxoSmithKline plc, GSK is 1062888.

With a target price of 48.67, can GlaxoSmithKline plc, GSK reach this target? Looking at the value indicators of GlaxoSmithKline plc, GSK. GlaxoSmithKline plc has a P/E of 3216.43 and a forward P/E of 17.06. Perhaps the more useful indicator than P/E, is PEG which has a value of 321.64. GlaxoSmithKline plc also has a P/S and a P/B of 3.3 and 145.26 respectively. For P/cash, GlaxoSmithKline plc has a value of 17.78, while it is *TBA for P/free cash flow.

At the current price of 45.17, GlaxoSmithKline plc has a dividend yield of 4.89%. We see a return on equity of 0.90%.

Looking more long-term GlaxoSmithKline plc, is projected to get an EPS growth for the next five years of 10.00%. In the short-term an EPS growth of 15.89% in the next year is forecasted. This is after a EPS growth of 204.10% for this year and for the last five years a 40.20% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Stephen Butters

Leave a Comment